JPRN-UMIN000006266已完成未知
CCR5 antagonist maraviroc's effect to osteoclasts in human - MVC Bone Study
ational Center for Global Health and Medicine0 个研究点目标入组 10 人开始时间: 2011年9月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •- Those who are not suited for maraviroc (whose HIV strain to be CXCR4 tropism) - Others who the principle investigator physician considered to be excluded
研究者
相似试验
终止
不适用
Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis ImmunophenotypesSarcoidosisNCT02134717Kevin F. Gibson3
已完成
1 期
Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell TransplantationHematopoietic Stem Cell TransplantationGraft-versus-host DiseaseNCT00948753Abramson Cancer Center at Penn Medicine38
已完成
3 期
Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/LamivudineHIV-1NCT00098293ViiV Healthcare916
已完成
不适用
Safety Study of Maraviroc's Effect on Human OsteoclastsAIDSHIV InfectionsNCT01428986National Center for Global Health and Medicine, Japan16
已完成
2 期
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected SubjectsHIV InfectionsNCT00098306ViiV Healthcare601